Melatonin affects the dynamic steady-state equilibrium of estrogen sulfates in human umbilical vein endothelial cells by regulating the balance between estrogen sulfatase and sulfotransferase

International Journal of Molecular Medicine

Volumn 36, Issue 6, 2015, Pages 1671-1676

  González, Alicia ^a   Martínez Campa, Carlos ^a   Alonso González, Carolina ^a   Cos, Samuel ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Estrogen sulfates; Estrogen sulfotransferase; Estrogens; Human umbilical vein endothelial cells; Melatonin; Sulfatase

Indexed keywords

ESTROGEN; ESTROGEN SULFATE; ESTROGEN SULFOTRANSFERASE; MELATONIN; STERYL SULFATASE; SULFATASE; UNCLASSIFIED DRUG; ANTIOXIDANT; ESTROGEN SULFATASE; ESTRONE SULFOTRANSFERASE; SULFATE; SULFOTRANSFERASE;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ESTROGEN BLOOD LEVEL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; SYNTHESIS; UMBILICAL VEIN ENDOTHELIAL CELL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIOXIDANTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MELATONIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFATASES; SULFATES; SULFOTRANSFERASES;

EID: 84945407140     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2360     Document Type: Article

References (43)

1. Germain D: Estrogen carcinogenesis in breast cancer. Endocrinol Metab Clin North Am 40: 473-484, 2011.
2. Pelekanou V and Leclercq G: Recent insights into the effect of natural and environmental estrogens on mammary development and carcinogenesis. Int J Dev Biol 55: 869-878, 2011.
3. Russo J and Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 102: 89-96, 2006.
4. Pasqualini JR and Chetrite GS: Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93: 221-236, 2005.
5. Stanway SJ, Delavault P, Purohit A, Woo LW, Thurieau C, Potter BV and Reed MJ: Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist 12: 370-374, 2007.
6. Pasqualini JR: The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 1654: 123-143, 2004.
7. Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N and Sasano H: Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 12: 701-720, 2005.
8. Suzuki T, Miki Y, Nakata T, Shiotsu Y, Akinaga S, Inoue K, Ishida T, Kimura M, Moriya T and Sasano H: Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. J Steroid Biochem Mol Biol 86: 449-454, 2003.
9. Cos S, González A, Álvarez-García V, Alonso-González C and Martínez-Campa C Melatonin and breast cancer: selective estrogen enzyme modulator actions. In: Advances in Cancer Drug Targets. Atta-ur-Rahman (ed). Vol 1. Bentham Science Publishers Sharjah, UAE, pp207-237, 2013.
10. Sasano H, Suzuki T, Nakata T and Moriya T: New development in intracrinology of breast carcinoma. Breast Cancer 13: 129-136, 2006.
11. Cos S and Sánchez-Barceló EJ: Melatonin and mammary pathological growth. Front Neuroendocrinol 21: 133-170, 2000.
12. Cos S and Sánchez-Barceló EJ: Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 15: 637-647, 2000.
13. Hill SM and Blask DE: Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 48: 6121 6126, 1988.
14. Blask DE, Sauer LA and Dauchy RT: Melatonin as a chronobiotic/anticancer agent: Cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2: 113-132, 2002.
15. Sánchez-Barceló EJ, Cos S, Fernández R and Mediavilla MD: Melatonin and mammary cancer: a short review. Endocr Relat Cancer 10: 153-159, 2003.
16. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 30: 118-128, 2006.
17. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso González C and Sánchez-Barceló EJ: Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 8: 691-702, 2008.
18. González A, Cos S, Martínez-Campa C, Alonso-Gonzalez C, Sánchez-Mateos S, Mediavilla MD and Sánchez-Barcelo EJ: Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res 45: 86-92, 2008.
19. Álvarez-García V, González A, Martínez-Campa C, Alonso González C and Cos S: Melatonin modulates aromatase activity and expression in endothelial cells. Oncol Rep 29: 2058 2064, 2013.
20. Cos S, Martínez-Campa C, González A, Álvarez-García V, Alonso-González C, Mediavilla MD and Sánchez-Barceló EJ: Melatonin and aromatase in breast cancer. Clin Cancer Drug 1: 54-64, 2014.
21. Cos S, Alvarez-García V, González A, Alonso-González C and Martínez-Campa C: Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (Review). Oncol Lett 8: 487-492, 2014.
22. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J Pineal Res 54: 373-380, 2013.
23. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Antiangiogenic effects of melatonin in endothelial cell cultures. Microvasc Res 87: 25-33, 2013.
24. Duncan L, Purohit A, Howarth NM, Potter BV and Reed MJ: Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: A potential therapeutic agent in breast cancer. Cancer Res 53: 298-303, 1993.
25. Falany CN, Krasnykh V and Falany JL: Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase. J Steroid Biochem Mol Biol 52: 529-539, 1995.
26. Barnabas O, Wang H and Gao XM: Role of estrogen in angiogenesis in cardiovascular diseases. J Geriatr Cardiol 10: 377-382, 2013.
27. Chakrabarti S, Morton JS and Davidge ST: Mechanisms of estrogen effects on the endothelium: An overview. Can J Cardiol 30: 705-712, 2014.
28. Khalil RA: Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol 86: 1627-1642, 2013.
29. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, et al: Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57: 359-383, 2005.
30. Bulun SE, Chen D, Lu M, Zhao H, Cheng Y, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, et al: Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol 106: 81-96, 2007.
31. Chumsri S and Brodie A: Aromatase inhibitors and breast cancer. Horm Mol Biol Clin Investig 9: 119-126, 2012.
32. Chumsri S: Clinical utilities of aromatase inhibitors in breast cancer. Int J Womens Health 7: 493-499, 2015.
33. Shields-Botella J, Bonnet P, Duc I, Duranti E, Meschi S, Cardinali S, Prouheze P, Chaigneau AM, Duranti V, Gribaudo S, et al: In vitro and in vivo models for the evaluation of new inhibitors of human steroid sulfatase, devoid of residual estrogenic activity. J Steroid Biochem Mol Biol 84: 327-335, 2003.
34. Santner SJ, Ohlsson-Wilhelm B and Santen RJ: Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures. Int J Cancer 54: 119-124, 1993.
35. Hill SM, Spriggs LL, Simon MA, Muraoka H and Blask DE: The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett 64: 249-256, 1992.
36. Molis TM, Spriggs LL and Hill SM: Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 8: 1681-1690, 1994.
37. Cos S, Martínez-Campa C, Mediavilla MD and Sánchez Barceló EJ: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 38: 136-142, 2005.
38. Cos S, González A, Güezmes A, Mediavilla MD, Martínez-Campa C, Alonso-González C and Sánchez-Barceló EJ: Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 118: 274-278, 2006.
39. González A, Martínez-Campa C, Mediavilla MD, Alonso González C, Alvarez-García V, Sánchez-Barceló EJ and Cos S: Inhibitory effects of melatonin on sulfatase and 17β-hydroxysteroid dehydrogenase activity and expression in glioma cells. Oncol Rep 23: 1173-1178, 2010.
40. González A, Alvarez-García V, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin. Curr Cancer Drug Targets 10: 279-286, 2010.
41. Santner SJ and Santen RJ: Inhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by antiestrogens. J Steroid Biochem Mol Biol 45: 383-390, 1993.
42. Li Y, Xu Y, Li X, Qin Y and Hu R: Effects of PPAR-α agonist and IGF-1 on estrogen sulfotransferase in human vascular endothelial and smooth muscle cells. Mol Med Rep 8: 133-139, 2013.
43. Xu Y, Yang X, Wang Z, Li M, Ning Y, Chen S, Yin L and Li X: Estrogen sulfotransferase (SULT1E1) regulates inflammatory response and lipid metabolism of human endothelial cells via PPARγ. Mol Cell Endocrinol 369: 140-149, 2013.